Global R&D Pipeline
My Favorite
Hot Targets:
FRα
Back
Total number of drugs
107
Phase II and later clinical stages
10.3%
Involving companies
124
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luveltamab | Luveltamab | Monoclonal antibody | Neoplasms | FOLR1 antagonists | Sutro Biopharma, Inc. | Sutro Biopharma, Inc. | Clinical | - | - | - | - | - | - | - | - | - | Luveltamab | - | - | detail > | |
| Pasifolate Exatecan | Pasifolate Exatecan | Small molecule-drug conjugates | Neoplasms Nervous System Diseases Urogenital Diseases | FOLR1 antagonists TOP1 inhibitors | Elucida Oncology, Inc. | Elucida Oncology, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Pasifolate Exatecan | - | - | detail > | |
| LX-101(Lirum Therapeutics) | LX-101(Lirum Therapeutics) | Peptide drug conjugates | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases | FOLR1 antagonists IGF-1 modulators IGF-1R modulators | IGF Oncology LLC | IGF Oncology LLC | IND Application | - | - | - | - | - | - | - | - | - | LX-101(Lirum Therapeutics) | - | - | detail > | |
| GenSci140 | GenSci140 | Antibody drug conjugate (ADC) | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | FOLR1 antagonists TOP1 inhibitors | Changchun Genescience Pharmaceuticals Co., Ltd. | Changchun Genescience Pharmaceuticals Co., Ltd. | IND Application | IND Application | - | - | - | - | - | Cleavable linker | - | 6 | GenSci140 | - | - | detail > | |
| IBI3010 | IBI3010 | Antibody drug conjugate (ADC) | Neoplasms | FOLR1 antagonists TOP1 inhibitors | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics (Suzhou) Co. Ltd. | IND Approval | IND Approval | - | - | - | - | - | - | NT1 | 8 | IBI3010 | - | - | detail > | |
| Mirvetuximab | Mirvetuximab | Monoclonal antibody | Neoplasms | FOLR1 antagonists | ImmunoGen, Inc. | ImmunoGen, Inc. | Clinical | - | - | - | - | - | - | - | - | - | Mirvetuximab | - | - | detail > | |
| ITM-55D | ITM-55D | Diagnostic radiopharmaceuticals | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | FOLR1 modulators | Itm Isotope Technologies Munich SE | Itm Isotope Technologies Munich SE | Phase 1 | - | - | - | - | - | - | - | 18 F | - | ITM-55D | - | - | detail > | |
| CBP-1018 | CBP-1018 | Small molecule-drug conjugates | Neoplasms Urogenital Diseases | FOLR1 antagonists PSMA inhibitors Tubulin inhibitors | Coherent Biopharma Suzhou Co., Ltd. | Coherent Biopharma Suzhou Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | MMAE | - | CBP-1018 | - | - | detail > | |
| SIBP-A19 | SIBP-A19 | Antibody drug conjugate (ADC) | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | FOLR1 antagonists TOP1 inhibitors | Shanghai Institute of Biological Products Co., Ltd. | Shanghai Institute of Biological Products Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | VASGFG | DXd | 8 | SIBP-A19 | - | - | detail > | |
| FA-S2-POMA | FA-S2-POMA | Proteolysis-targeting chimeras (PROTAC) | Neoplasms | FOLR1 degraders | Icahn School of Medicine at Mount Sinai | Icahn School of Medicine at Mount Sinai | Preclinical | - | - | - | - | - | - | - | - | - | FA-S2-POMA | - | - | detail > |
Total 107 data
1
2
3
4
5
6
...
10
11
